Abstract:Background: Exendin-4 is an incretin mimetic agent approved for type 2 diabetes treatment. However, the required frequent injections restrict its clinical application. Here, the potential use of chitosan-coated poly (d,l-lactide-co-glycolide) (CS-PLGA) nanoparticles was investigated for intestinal delivery of exendin-4.Methods and results: Nanoparticles were prepared using a modified water-oil-water (w/o/w) emulsion solvent-evaporation method, followed by coating with chitosan. The physical properties, particle size, and cell toxicity of the nanoparticles were examined. The cellular uptake mechanism and transmembrane permeability were performed in Madin-Darby canine kidney-cell monolayers. Furthermore, in vivo intraduodenal administration of exendin-4-loaded nanoparticles was carried out in rats. The PLGA nanoparticle coating with chitosan led to a significant change in zeta potential, from negative to positive, accompanied by an increase in particle size of similar to 30 nm. Increases in both the molecular weight and degree of deacetylation of chitosan resulted in an observable increase in zeta potential but no apparent change in the particle size of similar to 300 nm. Both unmodified PLGA and chitosan-coated nanoparticles showed only slight cytotoxicity. Use of different temperatures and energy depletion suggested that the cellular uptake of both types of nanoparticles was energy-dependent. Further investigation revealed that the uptake of PLGA nanoparticles occurred via caveolin-mediated endocytosis and that of CS-PLGA nanoparticles involved both macropinocytosis and clathrin-mediated endocytosis, as evidenced by using endocytic inhibitors. However, under all conditions, CS-PLGA nanoparticles showed a greater potential to be transported into cells, as shown by flow cytometry and confocal microscopy. Transmembrane permeability analysis showed that unmodified and modified PLGA nanoparticles could improve the transport of exendin-4 by up to 8.9-and 16.5-fold, respectively, consistent with the evaluation in rats.Conclusion: The chitosan-coated nanoparticles have a higher transport potential over both free drug and unmodified particles, providing support for their potential development as a candidate oral delivery agent for exendin-4.

A Site-Specific PEGylated Analog of Exendin-4 with Improved Pharmacokinetics and Pharmacodynamics in Vivo

C-terminal Site-Specific PEGylated Exendin-4 Analog: A Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Diabetic Db/db Mice.

Development of a C‐Terminal Site‐Specific PEGylated Analog of GLP‐1 with Improved Anti‐Diabetic Effects in Diabetic Mice

Engineering a novel protease-based Exendin-4 derivative for type 2 antidiabetic therapeutics.

Site-specific Fatty Chain-Modified Exenatide Analogs with Balanced Glucoregulatory Activity and Prolonged in Vivo Activity.

The construction of long-acting exendin-4 analog and its hypoglycemic effect in diabetic mice

The Study on PEGylation and Biological Activity of Insulinotropic Analogues

Preparation and PEGylation of exendin-4 peptide secreted from yeast Pichia pastoris.

Exendin 4-Hapten Conjugate Capable of Binding with Endogenous Antibodies for Peptide Half-life Extension and Exerting Long-Acting Hypoglycemic Activity

The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo

Sustained Release of Exendin-4 from Tannic Acid/fe (III) Nanoparticles Prolongs Blood Glycemic Control in a Mouse Model of Type II Diabetes.

Glucose-Responsive Nanochaperones Mediate Exendin-4 Delivery for Enhancing Therapeutic Effects

Exenatide-loaded Glucose-Responsive Microspheres for Intelligent Diabetic Therapy

Recent Development of Exendin-4 and Its Analogs

Systematic Design of Trypsin Cleavage Site Mutated Exendin4-Cysteine 1, an Orally Bioavailable Glucagon-Like Peptide-1 Receptor Agonist

Preparation, Characterization, and in Vitro and in Vivo Investigation of Chitosan-Coated Poly (D,l-Lactide-co-glycolide) Nanoparticles for Intestinal Delivery of Exendin-4

Long-Acting Release Formulation of Exendin-4 Based on Biomimetic Mineralization for Type 2 Diabetes Therapy

Site-specific N-terminal PEGylation-based controlled release of biotherapeutics: An application for GLP-1 delivery to improve pharmacokinetics and prolong hypoglycemic effects

Expression, Purification, and C-terminal Site-Specific PEGylation of Cysteine-Mutated Glucagon-Like Peptide-1

Characterization of a site-specific PEGylated analog of exendin-4 and determination of the PEGylation site.

Bioactivity and Structure of Analogues of Exendin-4